Provided here is a comprehensive examination of the basicand clinical condition of three innovative and promisingapproaches to cancer therapy, which may support or evensubstitute chemotherapy: differentiation, immunomodulation,and inhibition of angiogenesis.Differentiation shouldnormalize neoplastic cells and makethem compatible with the host. Its feasibility withretinoids, interferons, chemotherapeutic and other agents isdiscussed. Modulation by biological agents, cytotoxiceffector cells and drugs is considered in attempts toboost endogenous antitumour defenses and/or to renderneoplastic…mehr
Provided here is a comprehensive examination of the basicand clinical condition of three innovative and promisingapproaches to cancer therapy, which may support or evensubstitute chemotherapy: differentiation, immunomodulation,and inhibition of angiogenesis.Differentiation shouldnormalize neoplastic cells and makethem compatible with the host. Its feasibility withretinoids, interferons, chemotherapeutic and other agents isdiscussed. Modulation by biological agents, cytotoxiceffector cells and drugs is considered in attempts toboost endogenous antitumour defenses and/or to renderneoplastic cells more susceptible to the immune attack ofthe host. Finally, the important aspect of interfering withtumour blood vessel development and function is takeninto account.Consideringthe importance that chemotherapy has in cancertreatment and in view of a more and more integratedstrategy, the relationship between the aforementionedapproaches and chemotherapeutic agents and chemoresistanceis treated in detail.
Colon cancer cell differentiation as related to methotrexate and 5-fluorouracil resistance.- The control of cell multiplication and differentiation in human myelomonocytic cells.- Signal transduction through the Epstein-Barr virus receptor in human B lymphocytes.- Signal transduction mechanisms as a target for cancer chemotherapy.- Therapeutic approaches for colon cancer based on transcriptional regulation of specific growth factors.- Interferon regulation of differentiation and mechanisms.- Induction of tumor cell differentiation as a mechanism of action of DNA-specific antitumor agents.- ATRA therapy in acute promyelocytic leukemia. A model for differentiation therapy.- Hemin is transported in human leukemia K562 cells and interacts with DNA sequences.- Immunomodulation by anticancer drugs in therapeutics.- Differential effects of low doses of structurally different anthracyclines on immunoglobulin production by mouse hybridoma B cells.- Chemical xenogenization of experimental tumors by antineoplastic drugs.- Reversal of drug resistance: synergistic anti-tumor cytotoxic activity by combination treatment with drug and TNF or toxins.- Immunomodulation in cancer patients treated with interleukin-2. Induction of non-specific and specific immune responses.- Potential role of tumor cell antigen modulation in cancer immunotherapy.- Effects of tumor necrosis factor-alpha on growth and doxorubicin sensitivity of multidrug resistant tumor cell lines.- Activation of macrophages by treatment of rat peritoneal cells with photofrin II and He-Ne laser 209.- Synergistic interaction between simvastatin and antineoplastic drugs on glioma cell growth.- CNS and cardiovascular effects of TNF-alpha.- Angiogenesis and angiogenesis factors in stages of carcinogenesis.- Cytokine regulation oftumor-associated macrophages: therapeutic implications.- The mechanism of lectin-mediated adhesion of human ovarian carcinoma cells.- Inhibitory effect of suramin and heparin-like drugs on experimental angiogenesis.- Role of gangliosides in the modulation of the angiogenic response.
Colon cancer cell differentiation as related to methotrexate and 5-fluorouracil resistance.- The control of cell multiplication and differentiation in human myelomonocytic cells.- Signal transduction through the Epstein-Barr virus receptor in human B lymphocytes.- Signal transduction mechanisms as a target for cancer chemotherapy.- Therapeutic approaches for colon cancer based on transcriptional regulation of specific growth factors.- Interferon regulation of differentiation and mechanisms.- Induction of tumor cell differentiation as a mechanism of action of DNA-specific antitumor agents.- ATRA therapy in acute promyelocytic leukemia. A model for differentiation therapy.- Hemin is transported in human leukemia K562 cells and interacts with DNA sequences.- Immunomodulation by anticancer drugs in therapeutics.- Differential effects of low doses of structurally different anthracyclines on immunoglobulin production by mouse hybridoma B cells.- Chemical xenogenization of experimental tumors by antineoplastic drugs.- Reversal of drug resistance: synergistic anti-tumor cytotoxic activity by combination treatment with drug and TNF or toxins.- Immunomodulation in cancer patients treated with interleukin-2. Induction of non-specific and specific immune responses.- Potential role of tumor cell antigen modulation in cancer immunotherapy.- Effects of tumor necrosis factor-alpha on growth and doxorubicin sensitivity of multidrug resistant tumor cell lines.- Activation of macrophages by treatment of rat peritoneal cells with photofrin II and He-Ne laser 209.- Synergistic interaction between simvastatin and antineoplastic drugs on glioma cell growth.- CNS and cardiovascular effects of TNF-alpha.- Angiogenesis and angiogenesis factors in stages of carcinogenesis.- Cytokine regulation oftumor-associated macrophages: therapeutic implications.- The mechanism of lectin-mediated adhesion of human ovarian carcinoma cells.- Inhibitory effect of suramin and heparin-like drugs on experimental angiogenesis.- Role of gangliosides in the modulation of the angiogenic response.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826